Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN : L85195TG1984PLC004507 | |
| Tel :+91 40 4900 2900 | |
| Fax :+91 40 4900 2999 | |
| Email : mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. | ||
| BSE Limited | "Exchange Plaza" | ||
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | ||
| Mumbai - 400 001 | Mumbai - 400 051 | ||
| Fax Nos.: | 022-22723121 / 22723719 / | Fax Nos.: | 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
Please find enclosed a Press Release on
"Dr. Reddy's to release Q3 FY18 results on January 25, 2018 Earnings call slated for January 25, 6.30 PM IST / 8.00 AM
This is for your information.
CC: New York Stock Exchange Inc. (Stock Code: RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, | SAUNAK SAVLA | Calvin Printer |
| Hyderabad - 500034. Telangana, India. | saunaks@drreddys.com | calvinprinter@drreddys.com |
| (Ph: +91-40-49002135) | (Ph: +91-40- 49002121) |
Dr. Reddy's to release
Q3 FY18 results on January 25, 2018 Earnings call slated for January 25, 6:30 PM IST / 8:00 AM EST
Hyderabad, India, January 16, 2018
Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Third Quarter ended December 31, 2017
on Thursday, January 25, 2018 after the Board Meeting. The results will be available on the Company's website www.drreddys.com
| Event | Date and Time | Medium | ||
| Release of financial results | January 25 th , after the Board Meeting | Email, Media, Company website, Business wire | ||
| Earnings Call | January 25 th , 6:30 PM IST / 8:00 AM EST | Hosted by the Company (Details below) | ||
| Webcast of Earnings Call | January 25 th , 6:30 PM IST / 8:00 AM EST through January 29 th | URL available on Company's website, www.drreddys.com | ||
| Transcript of the Earnings call | Will be available on the Company's website | URL available on Company's website, www.drreddys.com | ||
| Press meet presentation | Will be available on the Company's website | URL available on Company's website, www.drreddys.com |
Following the release, the management of
the Company will host an earnings call to discuss the Company's financial performance. (Dial In and other details given
audio webcast of the earnings call will be available to all interested parties at www.drreddys.com.
Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any
necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The
replay will be available 2 hours after the earnings call, through January 29th, 2018. For play back dial in phone No:
022 3065 2322, and ID: 375#.
| Conference Dial-In Numbers | |
| Primary Number: | +91 22 3960 0616 |
| The numbers listed above are universally accessible from all networks and all countries. | |
| Local Access Number: | Accessible from all major carriers except BSNL/MTNL. 3940 3977 Available in Ahmedabad, Bangalore, Chandigarh, Chennai, NCR (Delhi, Gurgaon, Noida), Hyderabad, Jaipur, Kochi, Kolkata, Lucknow, Pune Accessible from all carriers. |
| International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to any of the
other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions
on asking questions before and during the call.
Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products
and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major
therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's
operates in markets across the globe. Our Major markets include - USA, India, Russia & CIS countries, and Europe. For
more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration
The company assumes no obligation to update any information